louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05938777: Non-Stage-Matched Intervention to Enhance High School Female Students' Readiness to Engage in Regular Physical Exercise
Official title: Efficacy of The Transtheoretical Model of Change in Enhancing High School Female Students' Readiness to Engage in Regular Physical Exercise: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Engaging in Regular Physical Exercise
Keywords: Health Behavior
Regular Physical Exercise
High School Female Students
Transtheoretical Model of Change
Lead sponsor: University of Baghdad
Sponsor class: OTHER
First posted: 2023-07-10
Enrollment: 144
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: PREVENTION

Brief summary: A non-stage-matched intervention based on the Transtheoretical Model of Change

Detailed description: The proposed intervention would be non-stage-matched intervention based on the Transtheoretical Model of Change.

The study sample would include high school female students (72 for the study group and 72 for the control group). The study participants will be randomly allocated and assigned into each of the study and control groups.

Participants will go through pretest, intervention, posttest 1, and posttest 2. There will be a 12-2eeks interval between the intervention and each of posttest 1 and posttest 2.

Eligibility criteria: Inclusion Criteria:

* High school female students who do not experience any physical disability

Exclusion Criteria:

* High school female students who experience any physical disability

Primary outcomes:
measure: Stages of Change Scale for Regular Physical Exercise
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03061877: Anxiety Depression and Rheumatoid Arthritis
Official title: The Effect of Anxiety and Depression on Treatment Response in Rheumatoid Arthritis
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rheumatoid Arthritis
Keywords: Rheumatoid arthritis
Anxiety
Depression
Lead sponsor: Sichuan Provincial People's Hospital
Sponsor class: OTHER
First posted: 2017-02-23
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People diagnosed with rheumatoid arthritis according to American College Rheumatology (ACR) criteria 2010

Brief summary: Anxiety and depression are highly prevalent in people with rheumatoid arthritis (RA).This study is to investigate the effect of anxiety and depression on treatment response in people with RA using observational longitudinal study design.


Eligibility criteria: Inclusion Criteria:

* People diagnosed with rheumatoid arthritis according to the American College Rheumatology (ACR) criteria 2010

Exclusion Criteria:

* none

Primary outcomes:
measure: Clinical remission
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Sichuan Provincial People's Hospital
name: Kun Zou, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06521853: Comparison Between PEEK With Autogenous Bone Graft and PEEK With Xenograft in Maxillary Sinus Augmentation
Official title: Comparison Between PEEK With Autogenous Bone Graft and PEEK With Xenograft in Maxillary Sinus Augmentation: Clinical, Radiographic and Histomorphometric Analysis. Randomized Clinical Trials.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Maxillary Sinus
Keywords: maxillary sinus augmentation ; bone graft
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-07-26
Enrollment: 12
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Comparison Between PEEK With Autogenous Bone Graft and PEEK With Xenograft in Maxillary Sinus Augmentation

Detailed description: Comparison Between PEEK With Autogenous Bone Graft and PEEK With Xenograft in Maxillary Sinus Augmentation: clinical, radiographic and histomorphometric analysis .

Eligibility criteria: Inclusion Criteria:

* posterior edentulous ridge less than 4mm in bone height

Exclusion Criteria:

* insufficient oral hygiene and motivation

Primary outcomes:
measure: bone height
timeFrame: after 6 months
Secondary outcomes:
measure: bone quality
timeFrame: after 6 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of dentistry Cairo university
Study officials:
References:
Clinical trial NCT00539253: Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
Official title: Assessment of Liver Cancer Response to Transcatheter Arterial Chemoembolization (TACE) Using Functional Triple-Phase MultiHance-Enhanced Magnetic Resonance Imaging (MRI)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatocellular Carcinoma
Keywords: liver cancer
transarterial chemoembolization
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sponsor class: OTHER
Collaborators: name: Bracco Diagnostics, Inc
First posted: 2007-10-04
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This research is being done to find out if using the contrast agent MultiHance can be used to show how a liver tumor responds to the chemotherapy given during Transcatheter Arterial Chemoembolization (TACE).

Detailed description: MultiHance is approved by the Food and Drug Administration (FDA) for use as a contrast material for Magnetic Resonance Imaging (MRI) scans of the central nervous system. It is believed that using MultiHance may be able to help doctors tell normal liver cells apart from active tumor and from tumor affected by the chemotherapy. In this way, MultiHance may improve the way patients with hepatocellular carcinoma are managed clinically.

We hypothesize that the Multi-Hance contrast material will provide better image definition of treated liver tumor(s) on MRI imaging in comparison to other commercially available contrast agents.

Eligibility criteria: Inclusion Criteria:

* Outpatients between the ages of 18 - 80 seen in the cardiovascular and interventional radiology clinic who are scheduled for TACE.
* International Normalized Ratio (INR) \<1.4
* Platelet count \> 80,000

Exclusion Criteria:

* Contraindications to TACE procedure
* Unable to have an MRI Scan
* Allergy or hypersensitivity reactions to gadolinium or any other ingredients, including benzyl alcohol
* Patients with sickle cell anemia , hemoglobinopathies and other hemolytic anemias
* Known clinical hypersensitivity or a history of asthma or allergic respiratory disorders
* Patients with advanced renal failure (those currently requiring dialysis or with a Glomerular Filtration Rate\<15cc/min)
* Pregnancy

Primary outcomes:
measure: Nodule Size
timeFrame: 3 months
measure: Nodule Enhancement
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: The Johns Hopkins Hospital
state: Maryland
Study officials:
affiliation: The Johns Hopkins University
name: Ihab Kamel
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05003453: The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema
Official title: The Effectiveness of a Topical Palmitoylethanolamide Formulation (Levagen+) for Reducing the Symptoms of Eczema Versus a Comparator
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Eczema, Atopic
Lead sponsor: RDC Clinical Pty Ltd
Sponsor class: INDUSTRY
First posted: 2021-08-12
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double blind, randomised, non-clinical study with 2 groups (1 investigational group and 1 comparator group) aiming to assess the effectiveness of PEA for reducing eczema severity compared to a base comparator moisturiser in healthy adults aged over 18 years.


Eligibility criteria: Inclusion Criteria:

* Adults (over 18)
* Suffering from atopic eczema with symptoms of redness, dry skin, scaling and/or itchiness on hands or arms
* Otherwise healthy
* Able to provide informed consent

Exclusion Criteria:

* Active allergic skin responses
* Unstable or serious illness (eg kidney, liver, GIT, heart conditions, diabetes, mood disorders, cancer)
* Use of immunosuppressive medication within the last 3 months
* Pregnant or lactating women
* Smokers
* Chronic past and/or current alcohol use (\>14 alcoholic drinks week)
* Allergic to any of the ingredients in active or comparator formula

  * An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.

Primary outcomes:
measure: Eczema area and severity index (SA-EASI)
timeFrame: Baseline prior to commencement, Week 2 and Week 4
Secondary outcomes:
measure: Change in itchiness (pruritus numerical rating scale)
timeFrame: Baseline prior to commencement, Week 2 and Week 4
measure: Change in topical anti-inflammatory use
timeFrame: Baseline prior to commencement, Week 2 and Week 4
measure: Patient eczema self assessment (Patient Orientated Eczema Measure)
timeFrame: Baseline prior to commencement, Week 2 and Week 4
measure: Change in Quality of Life (DQOL)
timeFrame: Baseline prior to commencement, Week 2 and Week 4
Other outcomes:
Locations:
city: Brisbane
country: Australia
facility: RDC Global Pty Ltd
state: Queensland
Study officials:
affiliation: The University of Queensland
name: David Briskey, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05730153: Advanced Platelet-rich Fibrin Combined With Open Debridement in Management of Suprabony Periodontal Defects
Official title: Clinical and Radiographic Evaluation of Advanced Platelet Rich Fibrin and Open Debridement in Management of Periodontal Suprabony Defects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Periodontitis, Adult
Lead sponsor: October University for Modern Sciences and Arts
Sponsor class: OTHER
First posted: 2023-02-15
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: in this clinical trial, patients with periodontal defects will be treated with advanced platelet-rich fibrin in conjunction with open debridement

Detailed description: two groups of patients with suprabony defects, one will be treated with advanced platelet-rich fibrin in conjunction with open debridement and the other will be treated with open debridement alone. subjects will be evaluated for evidence of bone formation after 6 months of therapy

Eligibility criteria: Inclusion Criteria:

* patients with periodontal suprabony defects.

Exclusion Criteria:

* pregnant females.
* smokers.
* systemic disease that contraindicate surgery

Primary outcomes:
measure: clinical evaluation
timeFrame: 6 months
Secondary outcomes:
measure: radiographic evaluation
timeFrame: 6 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Al-Azhar University, Faculty of Dentistry
Study officials:
References:
Clinical trial NCT06192953: Early Functional Proprioceptive Stimulation Post-stroke
Official title: Early Functional Proprioceptive Stimulation Post-stroke
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke (CVA) or TIA
Lead sponsor: Centre Hospitalier Universitaire de Nice
Sponsor class: OTHER
First posted: 2024-01-05
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of our study is to evaluate the impact of the use of Functional Proprioceptive Stimulation (FPS) on the recovery of the postural and motor functional capacities of the patient in the subacute phase of a stroke.

The hypothesis is that the use of FPS has a positive impact on the recovery of the patient's functional abilities, as well as on the duration of treatment until the sit/stand transfers are completed.

To evaluate this potential effect,there will be a randomization with two groups : one will have 5 sessions a week for 6 weeks maximum of SPF and the other groupe will have the same sessions but with the device stettled but not activated.


Eligibility criteria: Inclusion Criteria:

* Adult patient hospitalized at Cimiez University Hospital;
* Ischemic or hemorrhagic cerebrovascular accident (CVA) of less than two weeks;
* Hemiparesis requiring rehabilitation treatment;
* Patient with a SFPASS score ≤ 6;
* Patient affiliated to or beneficiary of a social security scheme;
* Signature of informed consent

Exclusion criteria :

* NIHSS \> 20;
* Muscle spasticity of the lower limbs requiring botulinum toxin injection
* Inability to understand rehabilitation instructions;
* Vulnerable people
* Pregnant women, parturients and breastfeeding mothers, persons deprived of their liberty by a judicial or administrative decision, persons hospitalized without consent and persons admitted to a health or social establishment for purposes other than research,
* Adults who are subject to a legal protection measure or who are unable to express their consent.

Primary outcomes:
measure: Score at the Short Form of Postural Assessment Scale for Stroke Patients (SFPASS)
timeFrame: Inclusion
measure: Score at the Short Form of Postural Assessment Scale for Stroke Patients (SFPASS)
timeFrame: Every week during 5 weeks maximum
measure: Score at the Short Form of Postural Assessment Scale for Stroke Patients (SFPASS)
timeFrame: 6 weeks
measure: Score at the Short Form of Postural Assessment Scale for Stroke Patients (SFPASS)
timeFrame: 10 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Nice
country: France
facility: CHU de Nice
Study officials:
References:
Clinical trial NCT02043353: The Natural History and Outcome of Sleep Disordered Breathing in Children
Official title: The Natural History and Outcome of Sleep Disordered Breathing in Children
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sleep Disordered Breathing
Obstructive Sleep Apnea
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2014-01-23
Enrollment: 2856
Sex: ALL
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy children 0-18 years old that underwent PSG evaluation at the Pediatric Sleep Center at Dana Children's hospital between 2005-2010

Brief summary: Sleep-disordered breathing in children is characterized by recurrent events of partial or complete upper airway obstruction during sleep, resulting in disruption of normal gas exchange (intermittent hypoxia and hypercapnia) and sleep fragmentation. The major symptom is snoring or noisy breathing. Sleep Disordered Breathing (SDB) is a wide spectrum of disorders that includes primary snoring, UARS and OSA. The main etiology for SDB in children is enlarged tonsils and adenoids and therefore the first line of treatment in pediatric SDB is adenotonsillectomy.

The objectives of this study are:

1. To investigate the natural history of primary snoring
2. To investigate the effect of seasonality on SDB severity
3. To compare the effect of adenoidectomy to adenotonsillectomy in the treatment of SDB in children
4. To characterize the children referred for repeated PSG following adenoidectomy or adenotonsillectomy and the indications for second PSG evaluation.


Eligibility criteria: Inclusion Criteria:

* healthy normally developing children that underwent PSG evaluation at the Tel Aviv Medical center between 2005-2010

Exclusion Criteria:

* Chronic medical and neurodevelopmental conditions.
* Congenital anomalies.

Primary outcomes:
measure: Snoring
timeFrame: 4 years
measure: OSA severity (AHI, mean SpO2, SPo2 nadir)
timeFrame: 4 years
measure: Daytime function
timeFrame: 4 years
Secondary outcomes:
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Sourasky Medical Center
Study officials:
References:
Clinical trial NCT00001153: Visual Function and Ocular Pigmentation in Albinism
Official title: Visual Function and Ocular Pigmentation in Albinism
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Albinism
Albinism, Ocular
Albinism, Oculocutaneous
Keywords: Albinism
Ocular Albinism
Oculocutaneous Albinism
Tyrosinase Negative
Tyrosinase Positive
Lead sponsor: National Institutes of Health Clinical Center (CC)
Sponsor class: NIH
First posted: 2002-12-10
Enrollment: 130
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: To study the relationship between visual function and ocular (iris, retina/choroidal) pigmentation in patients with albinism and other hypomelanotic disorders. To identify the carrier state in relatives of patients with ocular albinism.

Detailed description: Visual function and ocular pigmentation are being studied in patients with albinism and other disorders associated with hypopigmentation. The degree of ocular pigmentation is assessed clinically by estimating the melanin content of the iris, retinal pigment epithelium, and choroid. Visual function is measured in the conventional manner to study central vision, and electrophysiological methods to detect a misrouting of the visual pathways. The purpose of this study is to document the visual deficit and the pigmentary changes of patients with albinism, to observe their natural course, and to determine whether misrouting of the visual pathways is present and is correlated with pigmentation.

Eligibility criteria: Patients have been recruited into the study by referral from an ophthalmologist or pediatrician.

Entrance into the study was dependent upon clinical evidence of decreased or absent pigmentation in skin, hair, and/or eyes.

The definition was purposefully broad to include the broad range of phenotype variations and clinical heterogeneity.

The purpose of the study id to be able to document iris and retina/choroidal pigmentation and correlated these finding with visual function.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: National Eye Institute (NEI)
state: Maryland
Study officials:
References:
citation: Apkarian P, Shallo-Hoffmann J. VEP projections in congenital nystagmus; VEP asymmetry in albinism: a comparison study. Invest Ophthalmol Vis Sci. 1991 Aug;32(9):2653-61.
citation: Bouzas EA, Caruso RC, Drews-Bankiewicz MA, Kaiser-Kupfer MI. Evoked potential analysis of visual pathways in human albinism. Ophthalmology. 1994 Feb;101(2):309-14. doi: 10.1016/s0161-6420(13)31336-0.
Clinical trial NCT00556153: [F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children
Official title: [F-18]Fluoro-DOPA PET Imaging of Brain Tumors in Children
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Brain Tumors
Keywords: brain tumors, children
Lead sponsor: Children's Hospital Medical Center, Cincinnati
Sponsor class: OTHER
First posted: 2007-11-09
Enrollment: 0
Sex: ALL
Minimum age (years): 5
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children ages 5-15 years, with brain tumors

Brief summary: The first phase of the study will investigate if there is increased uptake of \[F-18\]FDOPA in pediatric brain tumors when compared to normal brain tissue.

Detailed description: The first phase of the study will investigate if there is increased uptake of \[F-18\]FDOPA in pediatric brain tumors when compared to normal brain tissue. Tne subjects between ages 5 and 17 years will be studies, to determine if there is increased uptake of \[F-18\]FDOPA in pediatric brain tumors when compared to normal brain tissue. Drug safety will also be monitored.

Eligibility criteria: Inclusion Criteria:

* Documented brain tumor at diagnosis or relapse, including high grade glioma, low grade glioma, medulloblastoma including PNET, optic pathway glioma, brainstem glioma, ependymoma.

Exclusion Criteria:

* Pregnancy
* Requirement for sedation
* Lack of informed consent

Primary outcomes:
measure: Increased uptake of [F-18]FDOPA in pediatric brain tumors compared to contralateral normal brain tissue as measured by standardized uptake value and tumor/non-tumor uptake ratios
timeFrame: 15-30 minutes after IV administration
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Cincinnati Children's Hospital, Cincinnati, OH
name: Michael J Gelfand, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01486953: Pulmonary Mechanics During Minimally Invasive Repair of Pectus Excavatum
Official title: Phase 4 Study of Desflurane and Sevoflurane That Affect Pulmonary Mechanics During Minimally Invasive Repair of Pectus Excavatum
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Pectus Excavatum
Keywords: respiratory resistance
lung compliance
desflurane
sevoflurane
Lead sponsor: The Catholic University of Korea
Sponsor class: OTHER
First posted: 2011-12-07
Enrollment: 70
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of the current study was to compare the effects of sevoflurane and desflurane on respiratory mechanics in patients undergoing repair of pectus excavatum.

Detailed description: The minimally invasive technique for pectus excavatum repair was introduced by Nuss and colleagues using a metal bar to lift the depressed chest wall. This surgical procedure is usually done under general anesthesia with tracheal intubation. After inserting metal bar into the chest wall, decreased lung compliance was shown. Previous studies demonstrated that administering desflurane during anesthesia resulted in marked increases in respiratory mechanical parameters, especially in the children with airway susceptibility. Our primary hypothesis was that desflurane would cause an increase in respiratory resistance and a decrease in lung compliance compared to sevoflurane during repair of pectus excavatum.

Eligibility criteria: Inclusion Criteria:

* clinical diagnosis of Pectus Excavatum
* undergoing minimally invasive repair

Exclusion Criteria:

* younger than 15 year old
* history of upper respiratory tract infection within recent 2 weeks
* asthma
* chronic obstructive pulmonary disease
* previous treatment with bronchoactive drugs (B-agonist or antagonist, theophyline, anticholinergics and corticosteroid)
* history of neurological deficits

Primary outcomes:
measure: pulmonary mechanics
timeFrame: within the 2 hours during the surgery
Secondary outcomes:
measure: complication
timeFrame: within 72 hours after sugery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul St. Mary's Hospital
Study officials:
affiliation: Department of Anesthesiology, The Catholic University of Korea, Seoul St. Mary's Hospital
name: Jeong Eun Kim, M.D, Ph.D
role: PRINCIPAL_INVESTIGATOR
References: